Danaher Corporation $DHR Shares Sold by Allworth Financial LP

Allworth Financial LP trimmed its holdings in Danaher Corporation (NYSE:DHR) by 21.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 11,176 shares of the conglomerate’s stock after selling 2,993 shares during the quarter. Allworth Financial LP’s holdings in Danaher were worth $2,129,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Arizona State Retirement System grew its holdings in Danaher by 1.4% during the second quarter. Arizona State Retirement System now owns 176,736 shares of the conglomerate’s stock worth $33,665,000 after acquiring an additional 2,519 shares during the period. Lipe & Dalton lifted its holdings in Danaher by 4.4% in the second quarter. Lipe & Dalton now owns 21,358 shares of the conglomerate’s stock valued at $4,068,000 after acquiring an additional 900 shares during the period. Empirical Finance LLC lifted its holdings in Danaher by 3.3% in the second quarter. Empirical Finance LLC now owns 22,703 shares of the conglomerate’s stock valued at $4,324,000 after acquiring an additional 726 shares during the period. Nykredit A S purchased a new stake in Danaher in the 2nd quarter worth approximately $30,377,000. Finally, Amundi grew its stake in shares of Danaher by 10.4% during the 2nd quarter. Amundi now owns 2,883,536 shares of the conglomerate’s stock worth $549,256,000 after purchasing an additional 272,444 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Wells Fargo & Company cut their target price on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a report on Wednesday, July 22nd. Piper Sandler started coverage on shares of Danaher in a research report on Thursday, June 11th. They set a “neutral” rating and a $200.00 price target on the stock. HSBC cut their price objective on shares of Danaher from $270.00 to $230.00 and set a “buy” rating for the company in a report on Wednesday, June 3rd. Guggenheim decreased their price objective on shares of Danaher from $235.00 to $200.00 and set a “buy” rating for the company in a research report on Wednesday, July 22nd. Finally, Wolfe Research cut Danaher from an “outperform” rating to a “peer perform” rating in a research report on Monday, June 1st. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $228.91.

Danaher Trading Down 0.1%

Shares of NYSE:DHR opened at $200.30 on Friday. The business’s 50 day moving average price is $202.65 and its 200-day moving average price is $192.08. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80. The firm has a market capitalization of $140.81 billion, a price-to-earnings ratio of 35.58, a price-to-earnings-growth ratio of 2.50 and a beta of 0.78. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping the consensus estimate of $1.85 by $0.09. The company had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm’s revenue was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.77 EPS. On average, equities research analysts forecast that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Danaher Company Profile

Danaher Corporation (NYSE:DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its businesses support pharmaceutical and biotechnology research, biomanufacturing, clinical laboratories and healthcare providers.

The company’s portfolio includes bioprocessing technologies, laboratory instruments, consumables, reagents and software. Key businesses include Cytiva, which provides biomanufacturing solutions; Beckman Coulter, which supplies laboratory diagnostics and automation systems; Leica Biosystems, which develops pathology products; and IDT, which provides genomic and nucleic acid products.